| Trial ID: | L0294 |
| Source ID: | NCT04913090
|
| Associated Drug: |
XZP-5610
|
| Title: |
A Phase I Clinical Trial of XZP-5610 Tablets in Healthy Subjects
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Nonalcoholic Steatohepatitis (NASH)
|
| Interventions: |
Drug: XZP-5610 Tablet (for Part A)|Drug: Placebo to match XZP-5610 Tablet (for Part A)|Drug: XZP-5610 Tablet (for Part B)|Drug: Placebo to match XZP-5610 Tablet (for Part B)|Drug: XZP-5610 Tablet ???for "Part C1"???|Drug: XZP-5610 Tablet for "Part C2"
|
| Outcome Measures: |
Cmax|Tmax|AUClast|AUCinf|T1/2|CL/F|Vz/F|Subject incidence of adverse events for XZP-5610 versus placebo
|
| Sponsor/Collaborators: |
Xuanzhu Biopharmaceutical Co., Ltd.
|
| Gender: |
All
|
| Age: |
18 Years to 60 Years ?? (Adult)
|
| Phases: |
Phase 1
|
| Enrollment: |
112
|
| Study Type: |
Interventional
|
| Study Designs: |
Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
|
| Start Date: |
May 31, 2021
|
| Completion Date: |
March 4, 2022
|
| Results First Posted: |
--
|
| Last Update Posted: |
June 4, 2021
|
| Locations: |
Peking University Third Hospital, Beijing, China
|
| URL: |
https://ClinicalTrials.gov/show/NCT04913090
|
